BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bio Based Press - ECPv5.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bio Based Press
X-ORIGINAL-URL:https://www.biobasedpress.eu/nl/
X-WR-CALDESC:Evenementen voor Bio Based Press
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20181024T080000
DTEND;TZID=Europe/Paris:20181025T170000
DTSTAMP:20201230T213727
CREATED:20171218T095934Z
LAST-MODIFIED:20171218T095934Z
UID:11364-1540368000-1540486800@www.biobasedpress.eu
SUMMARY:Annual Congress on CRISPR-Cas9 Technology
DESCRIPTION:International conference of CRISPR Congress is a Research-scientific knowledge bridge\, that aims bring together multi-disciplinary luminaries for Thriving innovation in the Biotechnology. The scientific conferences have been carefully structured so as to share knowledge and thoughts through presentations and exhibitions. CRISPR Congress event with sessions covers all aspects of biotech-driven technique CRISPR and addresses the key issues currently affecting its researches. Attendees can look forward to hearing about the different strategies taken to improve ongoing research and decipher how to overcome technical limitations in research development. This conference is where pharm\, investors and Life Science companies find partners\, access innovation\, find funding and brainstorm the solutions to further their business needs. \n\n\nAnnual congress on CRISPR-Cas9 Technology\n“CRISPR” (pronounced “crisper”) stands for Clustered Regularly Interspaced Short Palindromic Repeats\, which are the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology. In the field of genome engineering\, the term “CRISPR” or “CRISPR-Cas9” is often used loosely to refer to the various CRISPR-Cas9 and -CPF1\, (and other) systems that can be programmed to target specific stretches of genetic code and to edit DNA at precise locations\, as well as for other purposes\, such as for new diagnostic tools. With these systems\, researchers can permanently modify genes in living cells and organisms and\, in the future\, may make it possible to correct mutations at precise locations in the human genome in order to treat genetic causes of disease. Other systems are now available\, such as CRISPR-Cas13’s\, that target RNA provide alternate avenues for use\, and with unique characteristics that have been leveraged for sensitive diagnostic tools\, such as SHERLOCK. \nCRISPR genome editing allows scientists to quickly create cell and animal models\, which researchers can use to accelerate research into diseases such as cancer and mental illness. In addition\, CRISPR is now being developed as a rapid diagnostic. \nStudies using in vitro (laboratory) and animal models of human disease have demonstrated that the technology can be effective in correcting genetic defects. Examples of such diseases include cystic fibrosis\, cataracts and Fanconi anemia\, according to a 2016 review article published in the journal Nature Biotechnology. These studies pave the way for therapeutic applications in humans. \nCRISPR technology has also been applied in the food and agricultural industries to engineer probiotic cultures and to vaccinate industrial cultures (for yogurt\, for example) against viruses. It is also being used in crops to improve yield\, drought tolerance and nutritional properties. \nOne other potential application is to create gene drives. These are genetic systems\, which increase the chances of a particular trait passing on from parent to offspring. \nHowever\, CRISPR-Cas9 is not without its drawbacks. \nThe genome-editing efficiencies can vary. According to the 2014 Science article by Doudna and Charpentier\, in a study conducted in rice\, gene editing occurred in nearly 50 percent of the cells that received the Cas9-RNA complex. Whereas\, other analyses have shown that depending on the target\, editing efficiencies can reach as high as 80 percent or more. \nThere is also the phenomenon of “off-target effects\,” where DNA is cut at sites other than the intended target. This can lead to the introduction of unintended mutations. \nTracks \nPlant and Animal Biotechnology \nCancer and stem cells \nGenome Editing Methods and Novel Tools \nTherapeutic Genome Editing \nGenome editing and gene regulation in human health \nGenome editing and gene regulation in industrial bacterial biotechnology \nGenome editing and gene regulation in industrial eukaryotic biotechnology \nCRISPR technologies beyond genome editing and gene regulation \nAchieving efficient delivery and editing \nHorizons of CRISPR biology \nCRISPR technologies and society
URL:https://www.biobasedpress.eu/nl/event/annual-congress-on-crispr-cas9-technology/
LOCATION:Boston\, Verenigde Staten
END:VEVENT
END:VCALENDAR